Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Surbhi Sidana

Assistant Professor

Stanford University

United States

Research Interests

Explore related searches

Articles (25)

Collaborators (7)

Hrishikesh Srinagesh

Stanford University

UNITED STATES

Christof Scheid

University of Cologne

Joaquín Martínez‐López

Universidad Complutense de Madrid

Crystal L. Mackall

Stanford University School of Medicine

UNITED STATES

Hsien Seow

Associate Professor

McMaster University

Brian J Scott

Stanford University School of Medicine

UNITED STATES

Otto Hannes Vogel

Professor of Pathology and Associate Chair for Neuropathology

Stanford University School of Medicine

UNITED STATES

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Surbhi Sidana

Research Interests

Explore related searches

Articles (25)

Collaborators (7)

Hrishikesh Srinagesh

Christof Scheid

Joaquín Martínez‐López

Crystal L. Mackall

Hsien Seow

Brian J Scott

Otto Hannes Vogel

Make your next move.

Surbhi Sidana

Research Interests

Explore related searches

Articles (25)

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Peripheral Nerve Infiltration by CAR T-cells in a Case of Mononeuritis Multiplex after Ciltacabtagene Autoleucel.

Superior Chronic Graft-versus-Host Disease–Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation

Second primary malignancy in multiple myeloma: does a prior malignancy matter?

Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma.

Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis.

Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases.

Brexu-cel plus dasatinib: Safety and feasibility of dasatinib pulses after brexucabtagene autoleucel to modulate CAR T cell activity in relapsed/refractory B cell acute lymphoblastic leukemia

Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.

Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy.

Idecabtagene vicleucel manufacturing and clinical value of out of specification products in relapsed and refractory MM.

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.

The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma.

Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucel Toxicity Reduces the Total Duration of CRS and ICANS.

FORTRESS-CART: Focused Observation and Risk Testing for Robust Evaluation of Safety in Chimeric Antigen Receptor T-Cell Therapy (CAR-T): Real-World Predictors of Second Primary Malignancies (SPMs) Among Patients Treated With CAR-T.

Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort.

Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study

Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis.

Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease.

A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis.

Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.

Organ responses with daratumumab therapy in previously treated AL amyloidosis.

Collaborators (7)

Hrishikesh Srinagesh

Christof Scheid

Joaquín Martínez‐López

Crystal L. Mackall

Hsien Seow

Brian J Scott

Otto Hannes Vogel

Make your next move.